Since the discovery of kanamycin in 1957,1 this antibiotic has been used clinically in conditions often treated with streptomycin or neomycin. Histopathologic evidence of ototoxicity2-6 similar to that seen from streptomycin and neomycin, and a lack of cochlear microphonic response and of Cr. VIII nerve action potentials2 have been reported in kanamycin toxicity. Comparison of cochlear microphonics between kanamycin-damaged and dihydrostreptomycin-damaged ears showed a much greater depression of response in patients demonstrating kanamycin in the serum 24 hours after the original injection. The histopathological changes reported were atrophy of the organ of Corti and a reduction of spiral ganglion cell population. Kanamycin B was found to be much more toxic than the original kanamycin.2 Typical concentrations of kanamycin used by previous investigators are as follows:
Hawkins: 50 mg. per kilogram for 75 days; 200 mg. per kilogram for 30, 50, 70, 75 days.
Owada: 250 mg.
REDDY JB, IGARASHI M. Changes Produced by Kanamycin: Early Histologic Manifestations in the Inner Ears of Cats. Arch Otolaryngol. 1962;76(2):146–150. doi:10.1001/archotol.1962.00740050152008
Monkeypox Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.